Published in J Neuroinflammation on January 09, 2008
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology (2015) 2.27
The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology (2010) 2.05
Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs (2014) 1.49
Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J Neurosci (2008) 1.45
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation (2012) 1.29
PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med (2008) 1.17
Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets (2011) 1.16
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol (2008) 1.08
The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics (2010) 1.03
Elimination of Microglia Improves Functional Outcomes Following Extensive Neuronal Loss in the Hippocampus. J Neurosci (2015) 1.00
Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation (2010) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J Neuroinflammation (2012) 0.98
Cognitive dysfunction with aging and the role of inflammation. Ther Adv Chronic Dis (2011) 0.92
Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener (2011) 0.91
Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes (2009) 0.90
Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res (2012) 0.90
Inflammation and aging: can endocannabinoids help? Biomed Pharmacother (2008) 0.89
Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med (2008) 0.89
AMPA-receptor trafficking and injury-induced cell death. Eur J Neurosci (2010) 0.89
Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation (2008) 0.89
Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics (2010) 0.88
Etanercept attenuates traumatic brain injury in rats by reducing brain TNF- α contents and by stimulating newly formed neurogenesis. Mediators Inflamm (2013) 0.87
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.86
Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol (2011) 0.85
Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha. Infect Immun (2009) 0.85
The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflammation (2014) 0.85
Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology (2014) 0.84
The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian J Psychiatry (2009) 0.84
Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. J Neurol (2009) 0.84
Search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiol Aging (2013) 0.83
Role of PPARs in Radiation-Induced Brain Injury. PPAR Res (2009) 0.83
The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener (2016) 0.82
A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease. Neural Plast (2015) 0.81
The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms. Exp Brain Res (2014) 0.81
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res (2008) 0.81
Is TNF a link between aging-related reproductive endocrine dyscrasia and Alzheimer's disease? J Alzheimers Dis (2011) 0.81
The effect of chronic periodontitis on serum levels of tumor necrosis factor-alpha in Alzheimer disease. Dent Res J (Isfahan) (2014) 0.80
6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation. J Neuroinflammation (2016) 0.79
Alzheimer's disease: new diagnostic and therapeutic tools. Immun Ageing (2008) 0.79
Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis (2014) 0.79
Glimepiride reduces CD14 expression and cytokine secretion from macrophages. J Neuroinflammation (2014) 0.79
Alzheimer's Disease: Exploring the Role of Inflammation and Implications for Treatment. Int J Alzheimers Dis (2015) 0.78
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation (2016) 0.77
Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy. J Neuroinflammation (2016) 0.77
Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs (2014) 0.76
Perispinal Delivery of CNS Drugs. CNS Drugs (2016) 0.76
Therapeutic Effects of TianDiJingWan on the Aβ 25-35-Induced Alzheimer's Disease Model Rats. Evid Based Complement Alternat Med (2015) 0.75
Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease. J Clin Cell Immunol (2016) 0.75
Targeting inflammation to influence cognitive function following spinal cord injury: a randomized clinical trial. Spinal Cord (2016) 0.75
LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1(ΔE9) transgenic mice. Alzheimers Res Ther (2016) 0.75
Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. Curr Alzheimer Res (2016) 0.75
Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction. Psychopharmacology (Berl) (2015) 0.75
Inflammation, Self-Regulation, and Health: An Immunologic Model of Self-Regulatory Failure. Perspect Psychol Sci (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci (2004) 10.35
Synaptic scaling mediated by glial TNF-alpha. Nature (2006) 6.76
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Synaptic plasticity: taming the beast. Nat Neurosci (2000) 5.80
Deficits in strategy application following frontal lobe damage in man. Brain (1991) 4.66
Control of synaptic strength by glial TNFalpha. Science (2002) 4.46
Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. Neurology (1985) 3.88
Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci (2005) 3.38
Behavioural report of single neuron stimulation in somatosensory cortex. Nature (2007) 3.30
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med (2007) 3.05
Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging (2005) 2.44
Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev (2003) 2.40
Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem (2006) 2.27
Regulation of CNS synapses by neuronal MHC class I. Proc Natl Acad Sci U S A (2007) 2.25
The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry (2007) 2.23
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol (2007) 2.02
Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging (2001) 2.00
Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol (2005) 1.94
Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med (2005) 1.78
TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res (2005) 1.77
Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol (2007) 1.75
AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci U S A (2006) 1.74
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett (1991) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res (2006) 1.61
Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol (2002) 1.59
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol (2007) 1.59
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed (2006) 1.56
Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging (2006) 1.51
TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J (1999) 1.48
Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci (2007) 1.44
The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging (2001) 1.43
Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci (2005) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett (1992) 1.38
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res (2007) 1.38
Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci (2005) 1.32
Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. FASEB J (2006) 1.28
Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets (2004) 1.26
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol (2003) 1.17
The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed (2006) 1.17
Elevation of tumor necrosis factor in head injury. J Neuroimmunol (1990) 1.15
Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci (2005) 1.15
Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans (2007) 1.13
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull (2003) 1.10
Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol (2006) 1.05
Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry (2004) 1.04
Glia: they make your memories stick! Trends Neurosci (2007) 1.04
Altered synaptic function in Alzheimer's disease. Eur J Pharmacol (2006) 1.04
Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev (2006) 1.03
Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res (2007) 1.01
Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem (2005) 1.00
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat (2005) 0.95
The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital J Anat Embryol (2007) 0.95
A cross-sectional study of the effects of age, education, and gender on the Boston Naming Test. Clin Neuropsychol (2007) 0.94
Glutamate induces the expression and release of tumor necrosis factor-alpha in cultured hypothalamic cells. Brain Res (2005) 0.92
Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res (1997) 0.90
Principia aetiologica: taking causality beyond Koch's postulates. J Med Microbiol (2007) 0.88
TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease. J Neural Transm (Vienna) (2006) 0.87
Mechanisms of synaptic homeostasis in Alzheimer's disease. Curr Alzheimer Res (2004) 0.82
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed (2006) 1.56
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol (2008) 1.08